At high elevations in the northern Rockies, mountain pine beetles are killing countless whitebark pine trees, a major source of food for wildlife including grizzly bears

With an 80-acre scale model of the 1.6 million-acre Everglades wetland system, scientists study how to restore the flow of water that was interrupted years ago

Introduced in 1934, the federal duck stamp contest has raised more than $1.2 billion and protected at least 6.5 million acres across the nation. Now, an art exhibition at Connecticut’s Bruce Museum honors the competition’s history

The Delaware Department of Natural Resources and Environmental Control (DNREC) and the Department of Agriculture (DDA) Forest Service are to celebrate World Wetlands Day today, Thursday, Feb. 2, by signing a cooperative agreement to manage and protect unique wetland communities that occur on state-owned forest, park and wildlife lands.

Industrialist Ratan Tata, who passed away at the age of 86, is credited with transforming the Tata Group's portfolio during his tenure as chairman to include products from salt to software to sports cars.

I am trying to remove the cdn_loop_breaker cells from the netlist. 
When I tried the below 2 things, genus synthesis tool removing the cdn_loop_breaker cells but while connecting the cdn_loop_breaker cell input to its proper connection, its somehow misleading the connections

Things i tried:
1.  remove_cdn_loop_breaker -instances *cdn_loop_breaker*
then i just ran remove_cdn_loop_breaker  comand without the -instances switch
2. remove_cdn_loop_breaker  
     
both of the above things are not providing the proper connections after removing the loop_breaker_cells

can anyone suggest the best possible workaround for this please?

Dear all, 

I'm trying to perform an LVS check using Calibre between a layout that was generated by Innovus and the initial netlist generated by Genus. However, once I hit Run LVS on Calibre, it reports the following warnings and recommends to stop the process:

Source netlist references but does not define more than 10 subckts:
DFD1BWP7T
DFKCND1BWP7T
DFKCNQD1BWP7T
DFKSND1BWP7T
DFQD1BWP7T
IND2D0BWP7T
INR2D0BWP7T
INVD0BWP7T
INVD2P5BWP7T
IOA21D0BWP7T
... (and more)

If I proceed the LVS process it shows lots of errors as shown in the following image:

Why Genus doesn't include the definition of those sub circuits in the generated netlist? Is this related to Flat/Hierarchy netlisting? 

I have included my Genus scripts as well as the generated netlist in the attachments (and here - if attachment don't work).

Many thanks,

Anas

I was trying to remove the cdn_loop_breaker cells from the netlist. 
When I tried the below 2 things, it removing the cdn_loop_breaker cells but while connecting the cdn_loop_breaker cell input to its proper connection, its somehow misleading the connections

Things i tried:
1.  remove_cdn_loop_breaker -instances *cdn_loop_breaker*
then i just ran remove_cdn_loop_breaker  comand without the -instances switch
2. remove_cdn_loop_breaker  
     
both of the above things are not providing the proper connections after removing the loop_breaker_cells

Dear all,

I defined two design variables in ADE Assembler, say V1 and V2, that define the voltage 1 and voltage 2 of a "vpulse" voltage source in my schematic.

Then, I define V1 = 1.0, and V2 = 2.0, run a transient simulation, and everything is as expexcted. The source provides pulses between 1.0 V and 2.0 V.

Next, I set V1 = 1.0:0.5:1.5, thereby creating a parametric sweep with 1.0 V and 1.5 V for V1. I keep V2 at 2.0 V. Then the simulation fails, and all I get is "netl err" in my Output Expressions and an error message that the results directory does not exist and nothing can be plotted: This is reasonable, as the results directory is deleted on starting a new simulation, and as there is no simulation result, none of my output expressions can be plotted.

WARNING (OCN-6040): The specified directory does not exist, or the directory does not contain valid PSF results.
        Ensure that the path to the directory is correct and the directory has a logFile and PSF result files.
WARNING (ADE-1065): No simulation results are available.
ERROR (WIA-1175): Cannot plot waveform signals because no waveform data is available for plotting.
One of the possible reasons can be that 'Save' check box for these signals are not selected in the Outputs Setup pane. Ensure that these check boxes are selected before you run the simulation.

Normally, this kind of para,metric sweep is not a problem, I have done this many times before. There must be something special in THIS PARTICULAR test bench or simulator setup. The trouble is, I don't get any useful error messages.

Does anyone know what might be the problem here OR where to find useful information to investigate further (log files stored somewhere)? Thank you!

Regards,

Volker

P.S. Using Corners instead does not help either. Running it through all values by hand works, though.

How could we inherit parameters from schematic to a layout netlist?

Those parameters are user defined parameter given in CDF and netlsiting in schematic.

Few volcanos come with more risk than Mexico's Popocatépetl, situated near Mexico City.  To mitigate danger, volcanologist Chiara Maria Petrone is trying to predict its next eruption

Local officials are beginning to certify the results of this year's presidential election in a process that, so far, has been playing out quietly, in stark contrast to the tumultuous certification period four years ago that followed then-President Donald Trump's loss.

It is a surprisingly common peril among analysts: we don’t have the data to answer the question we’re interested in, so we answer a related question where we do have data. Unfortunately, the new answer turns out to shed no light on the original interesting question.

This is sometimes referred to as the Streetlight Effect – a phenomenon aptly illustrated by Mutt and Jeff over half a century ago:

This is the situation that the Tufts Center for the Study of Drug Development seems to have gotten itself into in its latest "Impact Report".  It’s worth walking through the process of how an interesting question ends up in an uninteresting answer.

So, here’s an interesting question:

My company owns a drug that may be approvable through FDA’s 505(b)(2) pathway. What is the estimated time and cost difference between pursuing 505(b)(2) approval and conventional approval?

That’s "interesting", I suppose I should add, for a certain subset of folks working in drug development and commercialization. It’s only interesting to that peculiar niche, but for those people I suspect it’s extremely interesting - because it is a real situation that a drug company may find itself in, and there are concrete consequences to the decision.

Unfortunately, this is also a really difficult question to answer. As phrased, you'd almost need a randomized trial to answer it. Let’s create a version which is less interesting but easier to answer:

What are the overall development time and cost differences between drugs seeking approval via 505(b)(2) and conventional pathways?

This is much easier to answer, as pharmaceutical companies could look back on development times and costs of all their compounds, and directly compare the different types. It is, however, a much less useful question. Many new drugs are simply not eligible for 505(b)(2) approval. If those drugs

Extreme qualitative differences of 505(b)(2) drugs. Source: Thomson Reuters analysis via RAPS

are substantially different in any way (riskier, more novel, etc.), then they will change the comparison in highly non-useful ways. In fact, in 2014, only 1 drug classified as a New Molecular Entity (NME) went through 505(b)(2) approval, versus 32 that went through conventional approval. And in fact, there are many qualities that set 505(b)(2) drugs apart.

So we’re likely to get a lot of confounding factors in our comparison, and it’s unclear how the answer would (or should) guide us if we were truly trying to decide which route to take for a particular new drug. It might help us if we were trying to evaluate a large-scale shift to prioritizing 505(b)(2) eligible drugs, however.

Unfortunately, even this question is apparently too difficult to answer. Instead, the Tufts CSDD chose to ask and answer yet another variant:

What is the difference in time that it takes the FDA for its internal review process between 505(b)(2) and conventionally-approved drugs?

This question has the supreme virtue of being answerable. In fact, I believe that all of the data you’d need is contained within the approval letter that FDA posts publishes for each new approved drug.

But at the same time, it isn’t a particularly interesting question anymore. The promise of the 505(b)(2) pathway is that it should reduce total development time and cost, but on both those dimensions, the report appears to fall flat.

• Cost: This analysis says nothing about reduced costs – those savings would mostly come in the form of fewer clinical trials, and this focuses entirely on the FDA review process.
• Time: FDA review and approval is only a fraction of a drug’s journey from patent to market. In fact, it often takes up less than 10% of the time from initial IND to approval. So any differences in approval times will likely easily be overshadowed by differences in time spent in development. 

But even more fundamentally, the problem here is that this study gives the appearance of providing an answer to our original question, but in fact is entirely uninformative in this regard. The accompanying press release states:

The 505(b)(2) approval pathway for new drug applications in the United States, aimed at avoiding unnecessary duplication of studies performed on a previously approved drug, has not led to shorter approval times.

This is more than a bit misleading. The 505(b)(2) statute does not in any way address approval timelines – that’s not it’s intent. So showing that it hasn’t led to shorter approval times is less of an insight than it is a natural consequence of the law as written.

Most importantly, showing that 505(b)(2) drugs had a longer average approval time than conventionally-approved drugs in no way should be interpreted as adding any evidence to the idea that those drugs were slowed down by the 505(b)(2) process itself. Because 505(b)(2) drugs are qualitatively different from other new molecules, this study can’t claim that they would have been developed faster had their owners initially chosen to go the route of conventional approval. In fact, such a decision might have resulted in both increased time in trials and increased approval time.

This study simply is not designed to provide an answer to the truly interesting underlying question.

[Disclosure: the above review is based entirely on a CSDD press release and summary page. The actual report costs $125, which is well in excess of this blog’s expense limit. It is entirely possible that the report itself contains more-informative insights, and I’ll happily update that post if that should come to my attention.]

Both anime screen N. American premieres at Anime Frontier on December 7

Thanks to Sivakumar ji for the ID

Hycleus zigzagus

Gear: Sony A7 III

Blister beetles are beetles of the family Meloidae, so called for their defensive secretion of a blistering agent,

cantharidin. About 7,500 species are known worldwide. Many are conspicuous and some are

aposematically colored, announcing their toxicity to would-be predators.

2nd February 2014 – Colombo, Sri Lanka Agriculture and wetlands should be managed in unison in order to conserve vital ecosystems and support the livelihoods of millions of people, according to a new report published to coincide with World Wetlands Day, today. Download the full media release Download the report

The post Millions affected, billions at stake: Scientists urge ‘wiser’ use of wetlands to tackle poverty and conserve ecosystems first appeared on International Water Management Institute (IWMI).

IWMI researchers comment on the importance of preserving Colombo's wetland ecosystem as the city becomes more vulnerable to flooding.

The post From wastelands to wetlands: The fight to save Sri Lanka’s natural flood buffers first appeared on International Water Management Institute (IWMI).

Startup employees often go on to found interesting ventures, basing their new work on the experience gained from their time building a company from scratch. But not all of those experiences are positive, and sometimes, a less-than-satisfactory exit can do more to fuel a founder’s fervor than anything else. In the case of Forward Earth’s […]

© 2024 TechCrunch. All rights reserved. For personal use only.

New York : Routledge, 2023.

Charlton-Trujillo, e. E., author

Michael Keaton visits WIRED to answers his most searched questions from Google. Was Michael Keaton the best Batman? Is he in the new Beetlejuice sequel “Beetlejuice Beetlejuice?” Was Michael Keaton a stand-up comedian? Where did Michael Keaton grow up? What does he remember about working with Quentin Tarantino? What was it like for Michael Keaton to make the film ‘Birdman’ with Alejandro González Iñárritu? Answers to each of these questions and more lie ahead on the WIRED Autocomplete Interview. Beetlejuice Beetlejuice releases September 6

Coimbatore’s Ukkadam Art District presents an immersive art experience as three artists reimagine the city’s rich biodiversity drawing attention to its wetlands, migratory birds and the impact of urbanisation

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline

Marketline